RAD data by YCharts.

Rite Aid (NYSE:RAD) has delivered impressive returns for investors lately, and the drugstore chain still has a lot of upside potential. Rite Aid is making considerable progress when it comes to both operations and financial performance, and the business is supported by strong secular tailwinds. Furthermore, Rite Aid remains attractively valued when compared against bigger competitors such as Walgreen (NASDAQ:WBA) and CVS Caremark (NYSE:CVS).

If Rite Aid continues increasing sales and expanding profit margin to levels similar to those of CVS Caremark and Walgreen, the company would deserve a materially higher valuation.

The slide show below contains some ideas for investors willing to take a deeper look at Rite Aid and its potential as an investment in the years ahead.

Andrés Cardenal has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.